Overview

By rapidly de-risking novel science and enriching partner pipelines with best-in-class molecules, i2020 helps accelerate early stage drug discovery platforms towards advanced lead and clinical candidate level within a two-year time framework. i2020's vast scientific and global resource network tailored specifically to the needs of early drug development programs allows it to take on projects in a wide array of therapeutic areas, from immunology to infectious diseases and beyond. By successfully leveraging agile development principles and flexible partnering business models, i2020 plans to co-create 15 diverse drug discovery programs in 2018.